2013
DOI: 10.1001/2013.jamaneurol.382
|View full text |Cite
|
Sign up to set email alerts
|

A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
12
0

Year Published

2013
2013
2020
2020

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 47 publications
(12 citation statements)
references
References 35 publications
0
12
0
Order By: Relevance
“…Latrepirdine stabilize and enhance mitochondrial membranes and functions. In a short duration trial, latrepirdine promoted cognitive improvement (MMSE) in mild to moderate HD patients [11,139]. At the time of writing this, a total of 13 clinical trials using latrepirdine have been reported on clinicaltrials.…”
Section: Latrepirdine (Dimebon)mentioning
confidence: 99%
See 1 more Smart Citation
“…Latrepirdine stabilize and enhance mitochondrial membranes and functions. In a short duration trial, latrepirdine promoted cognitive improvement (MMSE) in mild to moderate HD patients [11,139]. At the time of writing this, a total of 13 clinical trials using latrepirdine have been reported on clinicaltrials.…”
Section: Latrepirdine (Dimebon)mentioning
confidence: 99%
“…Chorea, incoordination, and rigidity are common motor symptoms due to neurotoxicity of mHTT, leading to brain atrophy of the striatum, thalamus, cerebellum, brain stem and cortex [6][7][8][9]. Clinically, HD includes juvenile HD (onset less than 21 years, and marked clinical symptoms), and late-onset HD (after the age of 60 years) [10][11][12]. Alcohol, drug, and tobacco abuse were associated with earlier onset of HD, and hasten motor onset in women.…”
Section: Introductionmentioning
confidence: 99%
“…Latrepirdine stabilize and surpass mitochondrial membranes and functions. In a short duration trail, latrepirdine caused cognitive improvement (MMSE) in mild to moderate HD patients [13,155]. Till today, total 13 clinical trials of latrepirdine reported on clinicaltrials.gov (NCT00497159, NCT01085266, NCT00920946, NCT00387270, NCT00988624, NCT00827034, NCT00990613, NCT00824590, NCT00931073, NCT00831506, NCT00788047, NCT00825084).…”
Section: Latrepirdine (Dimebon)mentioning
confidence: 99%
“…Chorea, incoordination, and rigidity are common motor symptoms due to neurotoxicity of mHTT, leading to brain atrophy of the striatum, thalamus, cerebellum, brain stem and the cortex [6][7][8][9]. Clinically, HD includes juvenile HD (onset less than 21 years, and a mark clinical symptoms), and late-onset HD (after the age 60 years) [10][11][12][13]. Alcohol, drug, and tobacco abuse were associated with earlier onset of HD and hasten motor onset in women.…”
Section: Introductionmentioning
confidence: 99%
“…Calcium, like ROS, has physiological roles, as discussed above. Therefore, it is not surprising that drugs such as dimebon (latrepiridine), an L-type calcium channel blocker were inefficient in clinical trials for both AD and HD (156158). …”
Section: H Calcium Ros and Neurodegenerationmentioning
confidence: 99%